EGFR and non-small cell lung carcinoma: Osimertinib, a third generation EGFR tyrosine kinase inhibitor (EGFR-TKI), was developed to counteract resistance to earlier EGFR-TKIs and has been approved for the management of locally advanced or metastatic NSCLC [2].